 |
Amphotericin B inhalation powder |
|---|---|
| Trade Name | |
| Orphan Indication | Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies |
| USA Market Approval | USA |
| USA Designation Date | 2005-12-15 00:00:00 |
| Sponsor | Novartis Pharmaceuticals Corporation;150 Industrial Road;San Carlos, California, 94070 |
